Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26319038 | 0.87 | MAPT (0.36) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL12872852 | 0.81 | MAPT (0.40) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL12930957 | 0.79 | MAPT (0.40) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL12961300 | 0.79 | MAPT (0.40) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL2705849 | 0.77 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL1296897 | 0.77 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL2705851 | 0.77 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL12943060 | 0.77 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL8914013 | 0.77 | ALDH1A1 (0.48) | MAPTALDH1A1MEN1KMT2APPM1B | |
| SCHEMBL24477334 | 0.76 | ALDH1A1 (0.40) | MAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215826-A1 | SOLID FORMS OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | ADAM JEAN-MICHEL | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215826-A1 | SOLID FORMS OF A PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVE | F2, PEPD, SERPINC1 | MAPT 2090/4885ALDH1A1 2996/4885MEN1 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.